Abstract:The gastrointestinal hormone, gastric inhibitory polypeptide (GIP), is synthesized and released from the duodenum and proximal jejunum postprandially. Its release depends upon several factors including meal content and pre-existing health status (ie. obesity, diabetes, age, etc.). It was initially discovered and named for its gastric acid inhibitory properties. However, its more physiologically relevant role appears to be as an insulinotropic agent with a stimulatory effect on insulin release and synthesis. Accordingly, it was later renamed glucose-dependent insulinotropic polypeptide because its action on insulin release depends upon an increase in circulating levels of glucose. GIP is considered to be one of the principle incretin factors of the enteroinsular axis. The GIP receptor is a G-protein-coupled receptor belonging to the family of secretin/VIP receptors. GIP receptor mRNA is widely distributed in peripheral organs, including the pancreas, gut, adipose tissue, heart, adrenal cortex, and brain, suggesting it may have other functions in addition to the ones mentioned above. An overactive enteroinsular axis has been suggested to play a role in the pathogenesis of diabetes and obesity. In addition to stimulating insulin release, GIP has been shown to amplify the effect of insulin on target tissues. In adipose tissue, GIP has been reported to (1) stimulate fatty acid synthesis, (2) enhance insulin-stimulated incorporation of fatty acids into triglycerides, (3) increase insulin receptor affinity, and (4) increase sensitivity of insulin-stimulated glucose transport. In addition, although controversial, lipolytic properties of GIP have been proposed. The mechanism of action of GIP-induced effects on adipocytes is unknown, and it is unclear whether these effects of GIP on adipocytes are direct or indirect. However, there is now evidence that GIP receptors are expressed on adipocytes and that these receptors respond to GIP stimulation. Given the location of its release and the timing of its release, GIP is an ideal anabolic agent and expanding our understanding of its physiology will be needed to determine its exact role in the etiology of diabetes mellitus and obesity.

Regulation of glucose and energy metabolism through actions of glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide

The physiology of glucagon-like peptide 1

Regulation of energy metabolism through central GIPR signaling

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

Glucagon-like Peptide-1 Drives Energy Metabolism on the Synaptic Highway.

GLP-1, a powerful physiological incretin: an update.

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

GLP-1 and Amylin in the Treatment of Obesity

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

The Role of Glucose-Dependent Insulinotropic Polypeptide in Fat Metabolism

Progress of extrapancreatic effects by glucagon-like peptide-1

The regulation of adipose tissue on gluconeogenesis

Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

GIP biology and fat metabolism

Glucagon and Regulation of Glucose Metabolism

Carbohydrate‐induced secretion of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1

Control of insulin secretion by GLP-1

The Possible Involvement of Glucagon-like Peptide-2 in the Regulation of Food Intake through the Gut-Brain Axis